Artivion Q3 revenue $87.9M (+14% YoY); raises FY2023 revenue and EBITDA guidance

ARTIVION, INC.

2023-Q3 EPS reported -$0.65 revenue$260,334,000

Revenue $87.9M, up 14% GAAP and 12% constant currency vs Q3 2022; net loss ($9.8M) or ($0.24)/share.
Non-GAAP net income $749k ($0.02/share) vs ($1.9M) loss a year ago; adjusted EBITDA up 34% to $13.9M.
Aortic stent graft revenue surged 30% GAAP (22% constant currency); On-X revenue up 14% (13% cc).
FY2023 revenue guidance raised to $349-351M (prior $342-350M); constant currency growth now 11-12%.
Expects 2023 adjusted EBITDA >$52M (+25% YoY); PERSEVERE trial enrollment nearing completion (90 of 93).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARTIVION, INC. reported the third quarter ended September 30, 2023 results: revenue $87.9 million, net income ($9.8) million, EPS ($0.24) per fully diluted common share. Guidance raised.

Period: the third quarter ended September 30, 2023
Revenue: $87.9 million
Net income: ($9.8) million
EPS: ($0.24) per fully diluted common share
Guidance: raised
Result: reported results

Exact text from the filing

Officer investors@artivion.com Phone: 770-419-3355 Artivion Reports Third Quarter 2023 Financial Results Third Quarter and Recent Business Highlights: • Achieved revenue of $87.9 million in the third quarter of 2023 versus $76.8 million in the third quarter of 2022, an increase of 14% on a GAAP basis and 12% on a non-GAAP constant currency basis • Net loss was

View on SEC.gov

Browse all earnings releases →

ARTIVION, INC. filing history →

Source: SEC EDGAR

accession 0000784199-23-000146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.